Vertex unveiled a series of new programs Wednesday and provided a glimpse of how it plans to use the cash from its cystic fibrosis portfolio to fuel deals that will continue to propel the company into pain and rare diseases.
privacy policy | terms of use | contact us | advertise | pharma jobs | pharma blogs | facebook | twitter
Copyright © 2024,